2017 Afternoon Breakout Sessions
2:15 pm - 3:15 pm

Expert speakers will take a deeper look into a variety of healthcare topics. Breakout sessions involve active participation and are intended to create vigorous discussion and lively debate. Attendees have the opportunity to attend two breakout sessions, one in the morning and one in the afternoon.

Payer Consolidation: Do Patients Benefit?
Format: Debate
Moderator: Fiona Scott Morton, PhD, Theodore Nierenberg Professor of Economics, Yale School of Management
Debate participants:
Eric H. Schultz, MBA, President and CEO, Harvard Pilgrim Health Care
Diana Moss, PhD, President, American Antitrust Institute
In an era of rising healthcare costs, several recent high-profile mega-mergers have been proposed. The Aetna-Humana deal was recently blocked by a federal judge, and the Cigna-Anthem deal is expected to face a similar conclusion, while the industry at large faces mounting antitrust challenges from the U.S. Justice Department. While the media has largely focused on the financial aspects of such deals, the potential impact on patients has been somewhat underrepresented in the consolidation conversation. How does consolidation in the health insurance market impact consumers? Would these mergers create efficiencies that give patients better products at lower cost? Or do they limit choice and increase premiums? Hear both sides in this debate!

From the Laboratory Bench to the Pharmacy Shelf: A Roadmap for Drug Approval
Format: Primer
Speakers:
Joseph S. Ross, MD, MHS, Associate Professor of Medicine and Public Health, Yale University School of Medicine
Frank S. David, MD, PhD, Managing Director, Pharmagellan
The FDA approval process for new drugs can seem long and arduous. Not only are there immense costs associated with carrying out clinical trials, but there is also major risk involved in the investment. Of the drugs that make it to phase 3, the FDA reports that approximately 30% will advance at which point pharma companies will have invested upwards of $40 million. From compound development to contract research organizations, this lecture will provide greater understanding for the often decade long journey to the pharmacy.

What VCs are Funding: The Next Big Thing in Healthcare
Format: Panel Discussion
Moderator: Donna Lecky, JD, MBA, Co-Founder, Health Venture
Participants:
Stephen Bloch, MD, General Partner, Canaan Partners
Andrew Hedin, MBA, Senior Associate, Bessemer Venture Partners
Katherine Miller, PhD, JD, Associate, Cooley LLP
Innovation in healthcare is progressing more quickly than ever before. From digital health and devices, to life sciences, to models of care provision and payment, VC firms bear witness to the newest ventures. How do ideas go from the drawing board to the marketplace? What corners of the health sector are ripe for disruption? Top healthcare and life sciences investors will share the ventures they are most excited about, how they discovered them, and what these ventures are doing to revolutionize healthcare.

The Promise and Challenges of Remote Patient Monitoring
Format: Panel Discussion
Moderator: Jared Augenstein, MPH, Manatt Health Solutions
Participants:
David Lee Scher, MD, Co-founder and CEO, DLS Healthcare Consulting
Jordan Asher, MD, MS, Chief Clinical Officer and Chief Innovation Officer, MissionPoint Health Partners
Michael Cantor, MD, JD, CMO, CareCentrix
Providers are beginning to utilize wireless healthcare devices to transmit real-time health data to clinicians, instantly reporting clinical metrics such as Blood Pressure, Pulse, Oxygenation and Blood-Sugar levels. This remote patient monitoring (RPM) comes with a host both of opportunities and challenges. It remains uncertain whether RPM has a measurable impact on clinical outcomes. The financial resources expended on RPM technologies may need to be justified by higher clinical quality and/or reduced costs in other areas of healthcare delivery. Data quality and security questions need to be addressed. Our panelists weigh in: will remote monitoring be successful in lowering costs and improving outcomes? Should healthcare organizations invest in RPM today?

Is the Role of the PCP Obsolete?
Format: Panel Discussion
Moderator: Joe Kimura, MD, MPH, CMO, Atrius Health
Participants:
Jay Parkinson, MD, Co-Founder and CEO, Sherpaa
Tobias Barker, MD, CMO, CVS/Minuteclinic
The primary care provider’s role in managing clinical care is shifting. As healthcare becomes more specialized, what place does traditional primary care take in the greater care continuum? How will clinical care coordination be managed as institutions consolidate and utilize big data? Can technology change the what we consider to be traditional primary care? Are managed care models framing what change can or cannot happen? This panel will cover the fragmentation of care, responsibilities around coordination, as well as the future of primary care.

Expanding Care Teams: Translating Evidence to Action for High Quality, Affordable Patient Care by Non-Physician Clinicians
Format: Panel Discussion
Moderator: William C. Kohlhepp, DHSc, PA-C, Dean of the School of Health Sciences, Quinnipiac University
Participants:
Benjamin R. Elkins, MPH, Director of Performance Improvement and Clinical Effectiveness Leadership Training, Stanford Health Care
Wendy Furniss, RNC, MS, Branch Chief of Healthcare Quality and Safety, CT Department of Public Health
Richard Stahl, MD, MBA, Senior Associate Dean for Strategic Relations, Frank H. Netter School of Medicine, Quinnipiac University
Deborah Sundal, MA, Vice President of Product Architecture, Enterprise Research and Development, UnitedHealth Group
There is convincing evidence that, for some fundamental elements of patient care, non-physician clinicians and non-clinical staff can deliver quality services and positive health outcomes at lower cost than traditional physician-centered approaches. This panel provides practical insights on the roles and settings in which non-physician clinicians, how they can be most effectively integrated into care teams, the costs and benefits of doing so, and the regulatory implications for more widespread adoption of more diverse care teams. Best practices for optimizing quality and cost by expanding the role of non-physician clinicians will be addressed.